Therapeutic Apheresis with NucleoCapture
NucleoCapture therapeutic NET removal has been designed to be highly complementary to existing extracorporeal modalities and can be easily incorporated into current plasmapheresis protocols.
NucleoCapture easily integrates into existing sepsis treatment modalities creating an add on product to standard care therapies.
Studies conducted at Uppsala University show excellent compatibility of NucleoCapture with an industry leading therapeutic apheresis system, kindly provided by Terumo BCT.
Connect the device to a standard plasma separation machine
Pump plasma through the NucleoCapture
Histone conjugated polymer beads directly contact plasma to remove NETs and other cell-free DNA fragments
Purified plasma is pumped back into the patient
NucleoCapture Device: Selective removal of Neutrophil Extracellular Traps from Blood
Santersus AG has developed a unique strategy for the treatment of patients in a variety of therapeutic areas through the selective extracorporeal removal of NETs from blood, using our patented NucleoCapture apheresis device.
NucleoCapture blood purification technology is based on biocompatible, highly porous polymer beads conjugated with proprietary human recombinant histone H1.3 protein. Histone H1.3 protein was developed by nature to be the ultimate human DNA binding and compacting protein and is a potent sensor and effector of the ancient innate immune defense system with single digit nanomolar DNA binding constants.
As a result, a single pass of NET-contaminated blood through our NucleoCapture device, results in over 95% removal of NETs.
In contrast to any potential pharmacological intervention targeting NETs, Santersus’ technology allows safe removal of NETs from blood without compromising the defensive function of neutrophils.